Sensus Healthcare LLC
Superficial radiation therapy for non-melanoma skin cancer
This article was originally published in Start Up
Executive Summary
Sensus Healthcare LLC has developed an alternative to Mohs surgery for non-melanoma skin cancers. Its SRT-100 is a mobile, low-energy radiotherapy system designed specifically for the cost-effective, noninvasive treatment of NMSCs. Unlike radiotherapy technologies used for treating other cancers, including linear accelerators and electron beam therapy, the radiation does not travel through the body and destroy healthy tissue.
You may also be interested in...
Medtech Start-Ups Innovate In Treating Advanced Skin Cancer
Nanotechnology, electroporation, and superficial radiotherapy are some of the tools device start-ups are deploying as alternatives to toxic drug regimens and surgery for treating skin cancer. We profile three emerging companies in this issue: OncoSec Medical, Sensus Healthcare, and Siva Therapeutics.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.